AMENDMENTS TO THE CLAIMS

Please amend the Claims as follows. Insertions are shown underlined while deletions are ~~struck through~~.

1 (currently amended): A composition for ~~preventing or~~ treating type I allergy selected from atopic dermatitis and ~~pollonosis~~pollinosis, comprising kaempferol-3-glucoside (astragalin) in an amount effective to ~~prevent or~~ treat type I allergy selected from atopic dermatitis and pollonosis.

2 (canceled)

3 (canceled)

4 (canceled)

5 (canceled)

6 (canceled)

7 (canceled)

8 (canceled)

9 (canceled)

10 (previously presented): The method according to claim 24 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

11 (previously presented): The method of claim 10 wherein the effective amount is from about 0.05 to about 1.5 mg per day per kg of body weight.

12 (previously presented): The method of claim 24 wherein the administration is selected from the group consisting of: orally, intravenously, topically, intramuscularly, intracutaneously, subcutaneously, intraperitoneally, and by aerosolization.

13 (previously presented): The method of claim 12, wherein the administration is orally, admixed with a food product.

14 (previously presented): The method of claim 13, wherein the food product is selected from the group consisting of: juice, soft drinks, teas, powdered soups, jelly, cookies, biscuits, cereal, crackers, candy, breads, noodles, fish paste, chewing gum, ice cream, and chocolate.

15 (previously presented): The method of claim 24 wherein the administration is between one and 4 doses per day.

16 (previously presented): The composition according to claim 1 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

17 (previously presented): The composition of claim 1 wherein the effective amount is from about 0.05 to about 1.5 mg per day per kg of body weight.

18 (previously presented): A pharmaceutical composition comprising the composition of claim 1 with a pharmaceutically acceptable carrier, diluent, or excipient.

19 (previously presented): The pharmaceutical composition of claim 18, wherein said carrier, diluent, or excipient is selected from the group consisting of: powders, lotions, ointments, binders, surfactants, moisturizers, fillers, extenders, wetting agents and food products.

20 (previously presented): The pharmaceutical composition of claim 18 further comprising: antiseptics, colerants, preservatives, antioxidants, aromatics, and food products.

21 (previously presented): The composition of claim 1 wherein said kaempferol-3-glucoside is extracted from plants or chemically synthesized.

22 (previously presented): The composition of claim 21, wherein said plants are selected from the group consisting of: persimmon, amachazuru, gymnema, guava, kuko, striped bamboo, jasmine, sugina, dokudami, loquat, sen-cha, and tien-cha.

23 (canceled)

24 (previously presented): A method for treating pollinosis in a subject, comprising:

administering to a subject who suffers from pollinosis an effective amount of kaempferol-3-glucoside to treat pollinosis.

25 (currently amended): A method for ~~preventing~~treating pollinosis in a subject, comprising:

administering to a subject who previously experienced pollinosis and expects to suffer from pollinosis in a specific season an effective amount of kaempferol-3-glucoside to ~~prevent~~treat pollinosis, prior to the season; and

~~continue~~continuing administering to the subject an effective amount of kaempferol-3-glucoside to ~~prevent~~treat pollinosis until the season is over.

26 (previously presented): The method according to claim 25 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

27 (previously presented): The method of claim 25 wherein the administration is selected from the group consisting of: orally, intravenously, topically, intramuscularly, intracutaneously, subcutaneously, intraperitoneally, and by aerosolization.

28 (previously presented): The method of claim 27, wherein the administration is orally, admixed with a food product.

29 (previously presented): The method of claim 28, wherein the food product is selected from the group consisting of: juice, soft drinks, teas, powdered soups, jelly, cookies, biscuits, cereal, crackers, candy, breads, noodles, fish paste, chewing gum, ice cream, and chocolate.

30 (previously presented): The method of claim 25 wherein the administration is between one and 4 doses per day.

31 (currently amended): A method for treating atopic dermatitis in a subject, comprising:

administering to a subject ~~with high serum IgE level~~ who suffers from atopic dermatitis an effective amount of kaempferol-3-glucoside to treat the atopic dermatitis.

32 (previously presented): The method according to claim 31 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

33 (previously presented): The method of claim 31 wherein the administration is selected from the group consisting of: orally, intravenously, topically, intramuscularly, intracutaneously, subcutaneously, intraperitoneally, and by aerosolization.

34 (previously presented): The method of claim 33, wherein the administration is orally, admixed with a food product.

35 (previously presented): The method of claim 34, wherein the food product is selected from the group consisting of: juice, soft drinks, teas, powdered soups, jelly, cookies, biscuits, cereal, crackers, candy, breads, noodles, fish paste, chewing gum, ice cream, and chocolate.

36 (previously presented): The method of claim 31 wherein the administration is between one and 4 doses per day.

37 (currently amended): A method for ~~preventing~~treating atopic dermatitis in a subject, comprising:

administering to a subject ~~with high serum IgE level~~ who suffers from atopic dermatitis an effective amount of kaempferol-3-glucoside before showing symptoms thereof to ~~prevent~~treat the atopic dermatitis.

38 (previously presented): The method according to claim 37 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

39 (previously presented): The method of claim 37 wherein the administration is selected from the group consisting of: orally, intravenously, topically, intramuscularly, intracutaneously, subcutaneously, intraperitoneally, and by aerosolization.

40 (previously presented): The method of claim 39, wherein the administration is orally, admixed with a food product.

41 (previously presented): The method of claim 40, wherein the food product is selected from the group consisting of: juice, soft drinks, teas, powdered soups, jelly, cookies, biscuits, cereal, crackers, candy, breads, noodles, fish paste, chewing gum, ice cream, and chocolate.

42 (previously presented): The method of claim 37 wherein the administration is between one and 4 doses per day.